BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1705 related articles for article (PubMed ID: 32297571)

  • 1. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral treatment of COVID-19.
    Şimşek Yavuz S; Ünal S
    Turk J Med Sci; 2020 Apr; 50(SI-1):611-619. PubMed ID: 32293834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.
    Jomah S; Asdaq SMB; Al-Yamani MJ
    J Infect Public Health; 2020 Sep; 13(9):1187-1195. PubMed ID: 32773212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for COVID-19: The reality and challenges.
    Jean SS; Lee PI; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
    Wang D; Li Z; Liu Y
    J Infect Public Health; 2020 Oct; 13(10):1405-1414. PubMed ID: 32684351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
    JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
    Lai CC; Chao CM; Hsueh PR
    J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of SARS-CoV-2: How far have we reached?
    Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
    Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
    CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
    Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic agents against COVID-19: What we know so far.
    Lu CC; Chen MY; Lee WS; Chang YL
    J Chin Med Assoc; 2020 Jun; 83(6):534-536. PubMed ID: 32243270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advance of promising targets and agents against COVID-19 in China.
    Duan Y; Zhu HL; Zhou C
    Drug Discov Today; 2020 May; 25(5):810-812. PubMed ID: 32198066
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
    Li C; Wang L; Ren L
    Virus Res; 2020 Sep; 286():198073. PubMed ID: 32592817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
    Habler K; Brügel M; Teupser D; Liebchen U; Scharf C; Schönermarck U; Vogeser M; Paal M
    J Pharm Biomed Anal; 2021 Mar; 196():113935. PubMed ID: 33548872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 86.